Answers are grounded in this paper and cite their sources.
Tumor-associated lymphoid architecture encompasses a spectrum of immune organization within the tumor microenvironment, ranging from loosely organized lymphoid aggregates to mature tertiary lymphoid structures (TLS) with distinct cellular compartments and germinal center activity. These structures are found across multiple solid tumor types and have been associated with prognosis and therapeutic outcomes, particularly responses to immunotherapy. Advances in high-dimensional tissue profiling, single-cell and spatial technologies have enabled increasingly detailed characterization of their cellular composition, functional states, and spatial organization. However, variation in terminology, detection criteria and analytical strategies continues to limit comparisons across studies and the development of reproducible clinical biomarkers based on lymphoid architecture. In this narrative review, we summarized the features and clinical relevance of lymphoid architecture across solid tumors, including melanoma, lung cancer, renal cell carcinoma, breast cancer, colorectal cancer and ovarian cancer. We further discuss the evolution of technologies used to study these structures and the bioinformatics approaches used to identify and characterize them across complementary data modalities. Finally, we discuss current challenges and future directions for standardizing lymphoid architecture assessment and applying biological and computational insights to the development of clinically relevant biomarkers and therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: